These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19906035)

  • 1. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment.
    Ghio M; Contini P; Negrini S; Proietti M; Gonella R; Ubezio G; Ottonello L; Indiveri F
    Transfusion; 2010 Mar; 50(3):547-55. PubMed ID: 19906035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion.
    Ghio M; Contini P; Setti M; Ubezio G; Mazzei C; Tripodi G
    J Clin Immunol; 2010 May; 30(3):384-92. PubMed ID: 20127276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
    Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
    Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components.
    Ghio M; Contini P; Ubezio G; Mazzei C; Puppo F; Indiveri F
    Transfusion; 2008 Aug; 48(8):1591-7. PubMed ID: 18466172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases.
    Rissmann A; Pieper S; Adams I; Brune T; Wiemann D; Reinhold D
    Pediatr Allergy Immunol; 2009 May; 20(3):261-5. PubMed ID: 18761651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I.
    Ottonello L; Ghio M; Contini P; Bertolotto M; Bianchi G; Montecucco F; Colonna M; Mazzei C; Dallegri F; Indiveri F
    Transfusion; 2007 Aug; 47(8):1395-404. PubMed ID: 17655583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.
    Kaveri S; Vassilev T; Hurez V; Lengagne R; Lefranc C; Cot S; Pouletty P; Glotz D; Kazatchkine MD
    J Clin Invest; 1996 Feb; 97(3):865-9. PubMed ID: 8609246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes.
    Inge TH; McCoy KM; Susskind BM; Barrett SK; Zhao G; Bear HD
    J Immunol; 1992 Jun; 148(12):3847-56. PubMed ID: 1602133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
    MacMillan HF; Lee T; Issekutz AC
    Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
    Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
    Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-avidity CD8lo T cells induced by incomplete antigen stimulation in vivo regulate naive higher avidity CD8hi T cell responses to the same antigen.
    Maile R; Pop SM; Tisch R; Collins EJ; Cairns BA; Frelinger JA
    Eur J Immunol; 2006 Feb; 36(2):397-410. PubMed ID: 16402405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
    Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
    Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
    Kosiewicz MM; Alard P; Liang S; Clark SL
    Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation.
    Ubiali F; Nava S; Nessi V; Frigerio S; Parati E; Bernasconi P; Mantegazza R; Baggi F
    Int Immunol; 2007 Sep; 19(9):1063-74. PubMed ID: 17660500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
    Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
    Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.
    Prasad NK; Papoff G; Zeuner A; Bonnin E; Kazatchkine MD; Ruberti G; Kaveri SV
    J Immunol; 1998 Oct; 161(7):3781-90. PubMed ID: 9759905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
    Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
    J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.